You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
A股異動丨創新藥概念股大升 冠昊生物直線拉昇錄得20cm升停 行業出海加速
格隆匯 03-28 10:15
A股創新藥大幅拉昇上升,其中,冠昊生物直線拉昇錄得20cm升停,首藥控股大升超14%,百花醫藥、潤都股份升停,翰宇藥業升超9%,百利天恒、榮昌生物、神州細胞、奧賽康等跟升。消息上,近期國產創新藥頻頻放出對外授權交易公吿。先是3月21日和鉑醫藥宣佈與阿斯利康達成戰略合作,雙方將共同研發針對免疫性疾病、腫瘤及其他多種疾病的新一代多特異性抗體療法。3月24日,減肥藥巨頭諾和諾德宣佈將以2億美元的首付款買下聯邦制藥的新型減肥藥UBT251;次日,默沙東又以最高17.7億美元的里程碑付款買下恒瑞醫藥的脂蛋白口服小分子項目,以獲得HRS-5346在大中華地區以外的全球範圍內開發、生產和商業化的獨家權利。山西證券近日表示,在出海難度最高的創新藥領域,中國企業逐步通過license out(對外授權)、國際多中心臨牀、中美雙報等方式進入發達國家市場。(格隆匯)

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account